Adrenal insufficiency: Etiology, diagnosis and treatment

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 17, Issue 3, 2010, Pages 217-223

  Neary, Nicola ^a   Nieman, Lynnette ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

ACTH stimulation; Adrenal insufficiency; Autoimmunity; Glucocorticoids

Indexed keywords

CHRONOCORT; CORTICOTROPIN; DUOCORT; GLUCOCORTICOID; HYDROCORTISONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEUKOCYTE ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; OCTREOTIDE; PLACEBO; PRASTERONE; PREDNISOLONE; PREDNISONE; STEROID 21 MONOOXYGENASE; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADRENAL FUNCTION; ADRENAL GLAND; ADRENAL GLAND TRANSPLANTATION; ADRENAL INSUFFICIENCY; ADRENOLEUKODYSTROPHY; ALLELE; AUTOIMMUNE DISEASE; BLEEDING; CLINICAL FEATURE; CONGENITAL ADRENAL HYPERPLASIA; CORTICOTROPIN TEST; CRITICAL ILLNESS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DISEASE PREDISPOSITION; HEMODIALYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROCORTISONE BLOOD LEVEL; HYPOPITUITARISM; INFECTION; ISOTOPE LABELING; KIDNEY GRAFT; LIVING DONOR; MAJOR HISTOCOMPATIBILITY COMPLEX; MENINGOCOCCEMIA; ORGAN TRANSPLANTATION; PROVOCATION TEST; QUALITY OF LIFE; RECTUS ABDOMINIS MUSCLE; REVIEW; STEROIDOGENESIS;

ADRENAL INSUFFICIENCY; ADRENOCORTICOTROPIC HORMONE; DEHYDROEPIANDROSTERONE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; QUALITY OF LIFE;

EID: 77951863360     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e328338f608     Document Type: Review

References (61)

1. Addison T. On the constitutional and local effects of disease of the supra-renal capsules. London: Samuel Highley; 1855.
2. Laureti S, Vecchi L, Santeusanio F, Falorni A. Is the prevalence of Addison's disease underestimated? J Clin Endocrinol Metab 1999; 84:1762.
3. Willis AC, Vince FP. The prevalence of Addison's disease in Coventry, UK. Postgrad Med J 1997; 73:286-288.
4. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365:2125-2136.
5. Mosser J, Douar AM, Sarde CO, et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 1993; 361:726-730. (Pubitemid 23070480)
6. Wolff AS, Erichsen MM, Meager A, et al. Autoimmune polyendocrine syndrome type 1 in Norway: phenotypic variation, autoantibodies, and novel mutations in the autoimmune regulator gene. J Clin Endocrinol Metab 2007; 92:595-603. (Pubitemid 46255301)
7. Erichsen MM, Lovas K, Skinningsrud B, et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94:4882-4890.
8. Triolo TM, Baschal EE, Armstrong TK, et al. Homozygosity of the polymorphism MICA5.1 identifies extreme risk of progression to overt adrenal insufficiency among 21-hydroxylase antibody-positive patients with type 1 diabetes. J Clin Endocrinol Metab 2009; 94:4517-4523.
9. Alizadeh BZ, Eerligh P, van der Slik AR, et al. MICA marks additional risk factors for type 1 diabetes on extended HLA haplotypes: an association and meta-analysis. Mol Immunol 2007; 44:2806-2812. (Pubitemid 46412504)
10. Zake LN, Ghaderi M, Park YS, et al. MHC class I chain-related gene alleles 5 and 5.1 are transmitted more frequently to type 1 diabetes offspring in HBDI families. Ann N Y Acad Sci 2002; 958:309-311. (Pubitemid 34592251)
11. Bornstein SR. Predisposing factors for adrenal insufficiency. N Engl J Med 2009; 360:2328-2339.
12. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293-300.
13. Rock EP, Goodman V, Jiang JX, et al. Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007; 12:107-113. (Pubitemid 46143508)
14. Speckart PF, Nicoloff JT, Bethune JE. Screening for adrenocortical insufficiency with cosyntropin (synthetic ACTH). Arch Intern Med 1971; 128:761-763.
15. Dorin RI, Qualls CR, Crapo LM. Diagnosis of adrenal insufficiency. Ann Intern Med 2003; 139:194-204. (Pubitemid 38124602)
16. Kazlauskaite R, Evans AT, Villabona CV, et al. Corticotropin tests for hypothalamic- pituitary-adrenal insufficiency: a metaanalysis. J Clin Endocrinol Metab 2008; 93:4245-4253. (Pubitemid 352789518)
17. Stewart PM, Clark PM. The low-dose corticotropin-stimulation test revisited: the less, the better? Nat Clin Pract Endocrinol Metab 2009; 5:68-69.
18. Mushtaq T, Shakur F, Wales JK, Wright NP. Reliability of the low dose synacthen test in children undergoing pituitary function testing. J Pediatr Endocrinol Metab 2008; 21:1129-1132.
19. Park YJ, Park KS, Kim JH, et al. Reproducibility of the cortisol response to stimulation with the low dose (1 microg) of ACTH. Clin Endocrinol (Oxf) 1999; 51:153-158.
20. Wade M, Baid S, Calis K, et al. Technical details influence the diagnostic accuracy of the 1 microg ACTH stimulation test. Eur J Endocrinol 2010; 162:109-113.
21. Agha A, Tomlinson JW, Clark PM, et al. The long-term predictive accuracy of the short synacthen (corticotropin) stimulation test for assessment of the hypothalamic- pituitary-adrenal axis. J Clin Endocrinol Metab 2006; 91:43-47. (Pubitemid 43069115)
22. Brien TG, Clerico A, Del Chicca MG, Zucchelli GC. The apparent free cortisol concentration and the free cortisol index: a comparative study. J Nucl Med Allied Sci 1981; 25:49-51. (Pubitemid 11055218)
23. Deutschbein T, Unger N, Mann K, Petersenn S. Diagnosis of secondary adrenal insufficiency in patients with hypothalamic-pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. Eur J Endocrinol 2009; 160:9-16.
24. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991; 72:39-45. (Pubitemid 21921653)
25. Bergthorsdottir R, Leonsson-Zachrisson M, Oden A, Johannsson G. Premature mortality in patients with Addison's disease: a population-based study. J Clin Endocrinol Metab 2006; 91:4849-4853. (Pubitemid 44917317)
26. Tomlinson JW, Holden N, Hills RK, et al. Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet 2001; 357:425-431. (Pubitemid 32156141)
27. Lovas K, Gjesdal CG, Christensen M, et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009; 160:993-1002.
28. Gurnell EM, Hunt PJ, Curran SE, et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 2008; 93:400-409.
29. Hahner S, Loeffler M, Fassnacht M, et al. Impaired subjective health status in 256 patients with adrenal insufficiency on standard therapy based on crosssectional analysis. J Clin Endocrinol Metab 2007; 92:3912-3922. (Pubitemid 47607641)
30. Weitzman ED, Fukushima D, Nogeire C, et al. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J Clin Endocrinol Metab 1971; 33:14-22.
31. Bleicken B, Hahner S, Loeffler M, et al. Influence of hydrocortisone dosage scheme on health related quality of life in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2009. [Epub ahead of print]
32. Bleicken B, Hahner S, Loeffler M, et al. Impaired subjective health status in chronic adrenal insufficiency: impact of different glucocorticoid replacement regimens. Eur J Endocrinol 2008; 159:811-817.
33. Lovas K, Husebye ES. Continuous subcutaneous hydrocortisone infusion in Addison's disease. Eur J Endocrinol 2007; 157:109-112. (Pubitemid 47162573)
34. Harbeck B, Kropp P, Monig H. Effects of short-term nocturnal cortisol replacement on cognitive function and quality of life in patients with primary or secondary adrenal insufficiency: a pilot study. Appl Psychophysiol Biofeedback 2009; 34:113-119.
35. Lennernas H, Skrtic S, Johannsson G. Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. Expert Opin Drug Metab Toxicol 2008; 4:749-758. (Pubitemid 352003197)
36. Verma S, Vanryzin C, Sinaii N, et al. A pharmacokinetic and pharmacodynamic study of delayed- and extended-release hydrocortisone (Chronocort) versus conventional hydrocortisone (Cortef) in the treatment of congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2009. [E-pub ahead of print]
37. Arlt W, Callies F, van Vlijmen JC, et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341:1013-1020. (Pubitemid 29451796)
38. Lovas K, Gebre-Medhin G, Trovik TS, et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003; 88:1112-1118. (Pubitemid 36337764)
39. Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab 1984; 59:551-555. (Pubitemid 14031806)
40. Arlt W, Justl HG, Callies F, et al. Oral dehydroepiandrosterone for adrenal androgen replacement: pharmacokinetics and peripheral conversion to androgens and estrogens in young healthy females after dexamethasone suppression. J Clin Endocrinol Metab 1998; 83:1928-1934. (Pubitemid 28496318)
41. Alkatib AA, Cosma M, Elamin MB, et al. A systematic review and meta-analysis of randomized placebo-controlled trials of DHEA treatment effects on quality of life in women with adrenal insufficiency. J Clin Endocrinol Metab 2009; 94:3676-3681.
42. Binder G, Weber S, Ehrismann M, et al. Effects of dehydroepiandrosterone therapy on pubic hair growth and psychological well being in adolescent girls and young women with central adrenal insufficiency: a double-blind, randomized, placebo-controlled phase III trial. J Clin Endocrinol Metab 2009; 94:1182-1190.
43. Kawano H, Yasue H, Kitagawa A, et al. Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men. J Clin Endocrinol Metab 2003; 88:3190-3195. (Pubitemid 36877493)
44. Williams MR, Dawood T, Ling S, et al. Dehydroepiandrosterone increases endothelial cell proliferation in vitro and improves endothelial function in vivo by mechanisms independent of androgen and estrogen receptors. J Clin Endocrinol Metab 2004; 89:4708-4715. (Pubitemid 39244492)
45. Rice SP, Agarwal N, Bolusani H, et al. Effects of dehydroepiandrosterone replacement on vascular function in primary and secondary adrenal insufficiency: a randomized crossover trial. J Clin Endocrinol Metab 2009; 94:1966-1972.
46. van der Steeg WA, Holme I, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol 2008; 51:634-642. (Pubitemid 351186873)
47. Singh I, Khan M, Key L, Pai S. Lovastatin for X-linked adrenoleukodystrophy. N Engl J Med 1998; 339:702-703.
48. Verrips A, Willemsen MA, Rubio-Gozalbo E, et al. Simvastatin and plasma very-long-chain fatty acids in X-linked adrenoleukodystrophy. Ann Neurol 2000; 47:552-553. (Pubitemid 30194620)
49. Engelen M, Ofman R, Dijkgraaf MG, et al. Lovastatin in X-linked adrenoleukodystrophy. N Engl J Med 2010; 362:276-277.
50. Grodstein E, Hardy MA, Goldstein MJ. A case of human intramuscular adrenal gland transplantation as a cure for chronic adrenal insufficiency. Am J Transplant 2009. [Epub ahead of print]
51. Melby JC, Spink WW. Comparative studies on adrenal cortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J Clin Invest 1958; 37:1791-1798.
52. Loriaux DL, Fleseriu M. Relative adrenal insufficiency. Curr Opin Endocrinol Diabetes Obes 2009; 16:392-400.
53. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976; 184:333-341.
54. Sprung CL, Caralis PV, Marcial EH, et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311:1137-1143.
55. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. J Am Med Assoc 2002; 288:862-871.
56. Annane D, Sebille V, Troche G, et al. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. J Am Med Assoc 2000; 283:1038-1045. (Pubitemid 30112218)
57. Hamrahian AH, Oseni TS, Arafah BM. Measurements of serum free cortisol in critically ill patients. N Engl J Med 2004; 350:1629-1638. (Pubitemid 38501164)
58. Sprung CL, Annane D, Keh D, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358:111-124.
59. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. Br J Clin Pharmacol 1998; 46:589-597. (Pubitemid 28522124)
60. Marik PE, Pastores SM, Annane D, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36:1937-1949.
61. Bendel S, Karlsson S, Pettila V, et al. Free cortisol in sepsis and septic shock. Anesth Analg 2008; 106:1813-1819.